Reverse Mergers Between German and U.S. Biotech Companies

Many private German biotech companies are facing difficulties in raising capital and, as a result, are finding public listings in more established markets increasingly attractive.  Some German biotechs have applied a creative structure to overcome these difficulties, such as the 'reverse merger' into a publicly held U.S. company, as a way of accessing US capital markets. This article explores this transaction model, commonly found within the U.S. biotech sector, as an attractive model for German biotechs.


Download PDF Back To Listing
Loading data